Explore
Validate
LearnAF376
antibody from R&D Systems
Targeting: CCL27
ALP, CTACK, CTAK, ESkine, ILC, PESKY, SCYA27, skinkine
Western blot
ImmunohistochemistryAntibody data
- Antibody Data
- Antigen structure
- References [2]
- Comments [0]
- Validations
- Immunohistochemistry [1]
- Blocking/Neutralizing [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- AF376 - Provider product page
- Provider
- R&D Systems
- Product name
- Human CCL27/CTACK Antibody
- Antibody type
- Polyclonal
- Description
- Immunogen affinity purified. Detects human CCL27/CTACK in direct ELISAs and Western blots. In Western blots, less than 2% cross-reactivity with recombinant mouse CCL27/CTACK is observed.
- Reactivity
- Human
- Host
- Goat
- Conjugate
- Unconjugated
- Antigen sequence
Q9Y4X3- Isotype
- IgG
- Vial size
- 100 ug
- Concentration
- LYOPH
- Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Submitted references Chemokine CCL27 is a novel plasma biomarker for identification the nasopharyngeal carcinoma patients from the Epstein-Barr virus capsid antigen-specific IgA seropositive population.
Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues.
Mao MJ, Xue N, Wang XP, Chi PD, Liu YJ, Huang Q, Dai SQ, Liu WL
BMC cancer 2018 Jan 2;18(1):9
BMC cancer 2018 Jan 2;18(1):9
Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues.
Jaeger J, Koczan D, Thiesen HJ, Ibrahim SM, Gross G, Spang R, Kunz M
Clinical cancer research : an official journal of the American Association for Cancer Research 2007 Feb 1;13(3):806-15
Clinical cancer research : an official journal of the American Association for Cancer Research 2007 Feb 1;13(3):806-15
No comments: Submit comment
Supportive validation
- Submitted by
- R&D Systems (provider)
- Main image
- Experimental details
- CCL27/CTACK in Human Skin. CCL27/CTACK was detected in immersion fixed frozen sections of human skin using Human CCL27/CTACK Antigen Affinity-purified Polyclonal Antibody (Catalog # AF376) at 15 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Goat HRP-AEC Cell & Tissue Staining Kit (red; Catalog # CTS009) and counterstained with hemotoxylin (blue). View our protocol for Chromogenic IHC Staining of Frozen Tissue Sections.
Supportive validation
- Submitted by
- R&D Systems (provider)
- Main image
- Experimental details
- Chemotaxis Induced by CCL27/CTACK and Neutralization by Human CCL27/CTACK Antibody. Recombinant Human CCL27/CTACK (Catalog # 376-CT) chemoattracts the BaF3 mouse pro-B cell line transfected with human CCR10/GPR2 in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Chemotaxis elicited by Recombinant Human CCL27/CTACK (1 µg/mL) is neutralized (green line) by increasing concentrations of Human CCL27/CTACK Antigen Affinity-purified Polyclonal Antibody (Catalog # AF376). At 55 μg/mL, this antibody will neutralize > 70% of the chemotactic effect.
